151004-96-5

Basic information

• Product Name: 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)-
• Synonyms: 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)-;(R)-2-Boc-3,4-dihydro-1H-isoquinoline-1-carboxylic acid;(R) -2- (tert-butoxycarbonyl) -1,2,3,4-tetrahydro-isoquinoline-carboxylic acid
• CAS NO: 151004-96-5
• Molecular Formula: C15H19NO4
• Molecular Weight: 277.31566
• Mol File: 151004-96-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)-(151004-96-5)
• EPA Substance Registry System: 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)-(151004-96-5)

Safety Data

• Hazardous Substances Data: 151004-96-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)is used as a key intermediate in the synthesis of drugs targeting neurological and psychiatric disorders. Its unique stereochemistry allows for the development of more effective and selective medications.
Used in the Treatment of Neurological and Psychiatric Disorders:
In the pharmaceutical industry, 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)is used as an active pharmaceutical ingredient for the treatment of conditions such as depression, anxiety, and neurodegenerative diseases. Its specific stereochemistry contributes to its efficacy and selectivity in modulating neurotransmitter systems and neural pathways associated with these disorders.
Used in Drug Synthesis:
1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)is used as a building block in the synthesis of various drug candidates. Its unique structural features and stereochemistry enable the development of novel compounds with improved pharmacological properties and therapeutic potential.
Overall, 1,2(1H)-Isoquinolinedicarboxylic acid, 3,4-dihydro-, 2-(1,1-diMethylethyl) ester, (1R)plays a significant role in the pharmaceutical industry, particularly in the development of drugs for the treatment of neurological and psychiatric disorders. Its specific stereochemistry and potential therapeutic applications make it a valuable compound for research and drug synthesis.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 151004-93-2 (R)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 41034-52-0 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 

Downstream Products

• 954239-58-8 (1R)-1-hydroxymethyl-2-[(tert-butyl) oxycarbonyl]-1,2,3,4-tetrahydroisoquinoline 
• 135526-78-2 (-)-Praziquantel 
• 765915-89-7 N-[(R)-1-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)]cyclohexanecarboxylic acid amide 

Relevant articles and documents

CRYSTAL FORM OF (R)-PRAZIQUANTEL AND PREPARATION METHOD AND APPLICATION THEREOF

The present invention relates to a crystal form of (R)-praziquantel and a preparation method and uses thereof. The X-ray diffraction pattern (CuKα radiation) of the crystal form of (R)-praziquantel at 25° C. shows the following diffraction peaks: 2-Theta=

CONFORMATIONAL AND BIOLOGICAL ANALYSIS OF &α-MSH FRAGMENT ANALOGUES WITH STERICALLY CONSTRAINED AMINO ACID RESIDUES

Conformational and biological analysis of the linear 4-11 fragment analogues, Ac-4>-α-MSH4-11-NH2 (II) and Ac-4.D-Phe7>-α-MSH4-11-NH2 (III) and related analogues have been undertaken.In solution, the peptide backbone is flexible, but in the case of D-Phe7 analogues an interaction of the His6.D-Phe7 and Arg8 amino acid side chain groups may be present based on the shielding patterns observed in the proton NMR and on comparison of NT1 values.The importance of the position 7 to the biological and conformational properties was further examined by substitution of either L- or D-phenylglycine (Pgl) or L- and D-1,2,3,4-tetrahydroisoquinoline carboxylic acid (Tic) for phenylalanine-7.Ac-4.Pgl7>-α-MSH4-11-NH2 (IV), Ac-4.D-Pgl>-α-MSH4-11-NH2 (V), Ac-4.Tic7>-α-MSH4-11-NH2 (VI), and Ac-4.D-Tic7>-α-MSH4-11-MH2 (VII) were prepared.These substituted analogues were examined for their biological activities and conformational properties with emphasis on the three-dimensional orientation of the aromatic ring in the position 7, and the effects of the aromatic ring on adjacent amino acids and on biological activities.The relative potencies of the analogues in the frog skin assay system were: II (1.00); III (118); IV (82.4); V (0.18); VI (0.18); and VII (0.14); and in the lizard skin bioassay they were: II (1.00); III (10.0); IV (0.14); V (0.005); VI (0.00025); and VII (0.01).On the basis of the NMR studies the L-phenylglycine substitution results in an enhanced ring stacking interaction between the phenyl ring of Pgl7 and the indole ring of Trp9.The 1,2,3,4-tetrahydroisoquinoline carboxylic acid (Tic) substitution leads to significant backbone restriction and an interaction of the alpha proton of His6 with the carbonyl of Glu5.The possible relationships of these effects to biological activity are discussed.